Therefore, there are now several trials conducted that introduce the latest class of checkpoint immune inhibitors that target PD-1/PDL-1 complexes into the therapeutic protocol of FIGO stage III or IV or relapsed ovarian cancer. This evidence concerns the gene PDCD1 and ovarian carcinoma.